Pomerantz LLP is investigating Ethos Technologies Inc. following allegations that the company misled investors by portraying itself as an automated AI platform while relying heavily on multilevel marketing (MLM) structures. A report revealed that 70% of Ethos's agents are tied to MLMs using aggressive tactics, with 83% of third-party agency revenue coming from just three MLM relationships. This news caused Ethos's stock to drop nearly 3% on October 1, 2026. The investigation will determine if Ethos and its executives engaged in securities fraud or other unlawful practices, potentially leading to a class action lawsuit.
Ethos Technologies Inc. is under investigation for alleged misleading practices. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 05:21 WIB: out of 150 priced US stocks, 97 rose and 52 fell. Notable movers include ANET at USD 191.75 with a 16.82% increase, SWKS at USD 70.87 down 16.79%, and CORZ at USD 14.45 up 15.55%.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
